دورية أكاديمية
Percutaneous Coronary Intervention in Stable Coronary Heart Disease -Is Less More?
| العنوان: | Percutaneous Coronary Intervention in Stable Coronary Heart Disease -Is Less More? |
|---|---|
| المؤلفون: | Figulla HR; Jena University Hospital; Department of Cardiology (CBF), Charité - Universitätsmedizin Berlin; Department of Internal Medicine II, University Hospital Regensburg; Cardiologicum Stuttgart; Cardiology practice, Munich and Stent Therapy at the Isar Heart Center, Munich; Department of Internal Medicine/Cardiology, Leipzig Heart Center., Lauten A, Maier LS, Sechtem U, Silber S, Thiele H |
| المصدر: | Deutsches Arzteblatt international [Dtsch Arztebl Int] 2020 Feb 28; Vol. 117 (9), pp. 137-144. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Deutscher Ärzte-Verlag Country of Publication: Germany NLM ID: 101475967 Publication Model: Print Cited Medium: Internet ISSN: 1866-0452 (Electronic) Linking ISSN: 18660452 NLM ISO Abbreviation: Dtsch Arztebl Int Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cologne : Deutscher Ärzte-Verlag |
| مواضيع طبية MeSH: | Percutaneous Coronary Intervention*, Coronary Disease/*surgery, Germany ; Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome |
| مستخلص: | Background: This review concerns the putative benefit of percutaneous coronary intervention (PCI) over optimal medical therapy (OMT) for symptomatic patients with stable angina pectoris, or for asymptomatic persons in whom screening tests have revealed coronary heart disease (CHD; this entity has been newly designated chronic coronary syndrome, or CCS). Moreover, it addresses the question whether the indications for which PCI is now performed in Germany on patients with CCS are consistent with current scientific knowledge. Methods: The pathophysiological concept of CHD and ischemia induction is discussed in the light of the scientific literature. This concept implies that PCI might be beneficial in the treatment of CCS. The benefit of PCI over OMT has now been evaluated in seven randomized trials (the so-called milestone trials). The current situation in Germany is presented here as well, on the basis of the available data. Results: The pathophysiological concept of CHD implies that the particular coronary artery stenoses that are likely to give rise to a myocardial infarction (the so-called vulnerable plaques) cannot be identified prospectively with current methods. Moreover, a coronary artery stenosis will not necessarily cause myocardial ischemia. All of the randomized trials carried out to date that have compared OMT to PCI-plus-OMT in patients with CCS have led to the conclusion that PCI, because it focuses on individual coronary artery stenoses, cannot prolong survival or lower the incidence of myocardial infarction over the long term. This remains the case even if a single coronary artery stenosis is known to be causing moderate or severe myocardial ischemia (a conclusion of the ISCHEMIA trial). A PCI performed only because the coronary stenosis or stenoses meet certain morphological criteria, without any demonstration of a resulting functional disturbance, is generally detrimental to the health of the patient, with rare exceptions, and is inconsistent with the recommendations of current guidelines. The number of PCIs being performed in Germany at present is high compared to other countries; this arouses concern that the indications for it may be dubious in many cases. Conclusion: Current data imply that PCI for CCS does not improve outcomes in a large percentage of cases. A symptomatic benefit exists only in patients with frequent angina pectoris. The selection of CCS patients for PCI needs to be more strictly bound to the recommendations of current guidelines, particularly in Germany. |
| References: | Circulation. 1995 Aug 1;92(3):657-71. (PMID: 7634481) J Am Coll Cardiol. 2019 Mar 5;73(8):964-976. (PMID: 30819365) N Engl J Med. 2009 Jun 11;360(24):2503-15. (PMID: 19502645) Eur Heart J. 2018 Sep 14;39(35):3314-3321. (PMID: 30137305) Am J Cardiol. 1992 Mar 15;69(8):729-32. (PMID: 1546645) Clin Res Cardiol. 2017 Feb;106(2):140-150. (PMID: 27599974) N Engl J Med. 2007 Apr 12;356(15):1503-16. (PMID: 17387127) Eur Heart J. 2020 Jan 14;41(3):407-477. (PMID: 31504439) Can J Cardiol. 2013 Apr;29(4):472-82. (PMID: 23010084) Circ J. 2010 Jan;74(1):24-33. (PMID: 19920359) Dtsch Arztebl Int. 2019 Mar 22;116(12):205-211. (PMID: 31056086) Circulation. 2005 Jun 7;111(22):2906-12. (PMID: 15927966) J Am Coll Cardiol. 1991 Oct;18(4):904-10. (PMID: 1894863) Herz. 2017 Feb;42(1):51-57. (PMID: 27255115) Eur Heart J. 2018 Sep 14;39(35):3322-3330. (PMID: 29850808) BMJ. 2014 Jun 23;348:g3859. (PMID: 24958153) J Am Coll Cardiol. 2011 Jul 26;58(5):510-9. (PMID: 21777749) Circulation. 2017 Nov 21;136(21):1993-2005. (PMID: 28847895) N Engl J Med. 2015 Nov 12;373(20):1937-46. (PMID: 26559572) N Engl J Med. 1996 Jun 27;334(26):1703-8. (PMID: 8637515) JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1303-1312. (PMID: 30553687) N Engl J Med. 2019 Jun 20;380(25):2418-2428. (PMID: 31216398) N Engl J Med. 2009 Jan 15;360(3):213-24. (PMID: 19144937) JAMA. 2005 Jun 15;293(23):2908-17. (PMID: 15956636) N Engl J Med. 2014 Sep 25;371(13):1208-17. (PMID: 25176289) Circulation. 2018 Feb 13;137(7):665-679. (PMID: 29142010) Lancet. 2018 Jan 6;391(10115):31-40. (PMID: 29103656) JAMA Intern Med. 2014 Feb 1;174(2):232-40. (PMID: 24296791) JAMA Cardiol. 2019 Mar 1;4(3):273-286. (PMID: 30810700) Am Heart J. 2018 Jul;201:124-135. (PMID: 29778671) N Engl J Med. 2018 Jul 19;379(3):250-259. (PMID: 29785878) |
| تواريخ الأحداث: | Date Created: 20200403 Date Completed: 20200803 Latest Revision: 20231113 |
| رمز التحديث: | 20231113 |
| مُعرف محوري في PubMed: | PMC7132080 |
| DOI: | 10.3238/arztebl.2020.0137 |
| PMID: | 32234189 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1866-0452 |
|---|---|
| DOI: | 10.3238/arztebl.2020.0137 |